ProCE Banner Activity

Long-Acting Injectable HIV Treatment and Prevention: Key Considerations for Women

Clinical Thought
Here is my take on important factors related to the use of long-acting HIV therapies in women, including key findings from several recent studies examining women’s preferences for oral vs long-acting injectable HIV treatment and prevention modalities.

Released: October 13, 2022

Expiration: October 12, 2023

No longer available for credit.

Share

Faculty

Yvonne Gilleece

Yvonne Gilleece, MB BCh, BAO

Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Yvonne Gilleece, MB BCh, BAO

Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom

Yvonne Gilleece, MB BCh, BAO: educational meetings: ViiV; consultant/advisor/speaker: Gilead Sciences, ViiV; conference sponsorship: Gilead Sciences.